<DOC>
	<DOCNO>NCT02992418</DOCNO>
	<brief_summary>The aim study investigate immunogenicity safety CYD dengue vaccine Tdap vaccine vaccine administer concomitantly sequentially . Primary Objectives : - To demonstrate non-inferiority humoral immune response Tdap booster dose concomitantly administer first dose CYD dengue vaccine compare sequential administration , measure 28 day Tdap booster dose - To demonstrate non-inferiority humoral immune response first dose CYD dengue vaccine concomitantly administer Tdap compare sequential administration , measure 28 day first dose CYD dengue vaccine . Secondary Objectives : - To demonstrate non-inferiority humoral immune response 3 dos CYD dengue vaccine first dose concomitantly administer Tdap compare sequential administration , measure 28 day third dose CYD dengue vaccine . - To describe humoral immune response baseline 28 day first third dos CYD dengue vaccine , group . - To describe humoral immune response Tdap vaccine baseline 28 day concomitant administration first dose CYD dengue vaccine compare sequential administration , group . - To describe safety CYD dengue vaccine Tdap booster dose injection group .</brief_summary>
	<brief_title>Study Tetravalent Dengue Vaccine Administered Concomitantly Sequentially With Adacel® Healthy Subjects</brief_title>
	<detailed_description>All participant receive CYD dengue vaccine accord 3-dose schedule administer 6 month apart , first dose CYD dengue vaccine administer either concomitantly sequentially booster dose Tdap vaccine , Adacel® . They assess immunogenicity safety .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Severe Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject age 9 60 year ( i.e. , day 9th birthday day prior 61th birthday ) day inclusion Subject good health , base medical history physical examination Informed consent form ( ICF ) assent form ( AF ) sign date subject ( base local regulation ) , and/or ICF sign date parent ( ) another legally acceptable representative ( independent witness require local regulation ) For subject age 9 11 year : know ( document ) receipt least 4 previous dos diphtheria toxoid , tetanus toxoid acellular pertussiscontaining ( DTaP ) vaccine , last dose within last 5 year prior enrolment OR For subject age least 12 year : know ( document selfreported ) receipt least 3 previous dos diphtheria toxoid , tetanus toxoid , whole cell pertussiscontaining ( DTwP ) vaccine , last dose within last 5 year prior enrolment Subject ( subject parent [ ] /legally acceptable representative ) able attend schedule visit comply trial procedure . Subject pregnant , lactating , childbearing potential ( consider nonchildbearing potential , female must premenarche postmenopausal least 1 year , surgically sterile , use effective method contraception abstinence least 4 week prior first vaccination least 4 week last vaccination ) Participation time study enrollment ( 4 week precede first trial vaccination ) plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure Planned receipt vaccine 4 week follow trial vaccination Previous vaccination dengue disease trial CYD dengue vaccine Receipt immune globulin , blood bloodderived product past 3 month , might interfere assessment immune response Known suspect congenital acquired immunodeficiency ( include HIV infection impair immune function ) ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) A previous severe reaction pertussis , diphtheria tetanus vaccine include immediate anaphylaxis , encephalopathy within 7 day seizure within 3 day receive vaccine Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine use trial vaccine contain substance Thrombocytopenia , contraindicate intramuscular vaccination Bleeding disorder receipt anticoagulant within 3 week precede inclusion , may contraindication intramuscular vaccination , discretion Investigator Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction , base Investigator 's judgment , may interfere subject 's ability comply trial procedure Chronic illness , opinion Investigator , stage might interfere trial conduct completion Identified Investigator employee Investigator direct involvement propose study , identify immediate family member ( i.e. , parent , spouse , natural adopt child ) Investigator employee direct involvement propose study Selfreported Human Immunodeficiency Virus ( HIV ) , Hepatitis B , Hepatitis C infection Personal history GuillainBarré syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Dengue Fever</keyword>
	<keyword>Dengue Hemorrhagic Fever</keyword>
	<keyword>CYD Dengue Vaccine</keyword>
	<keyword>Degavaxia®</keyword>
</DOC>